TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Adragos Pharma Kawagoe and Towa Pharmaceutical signed a basic agreement to establish a strategic collaboration for stable supply of off-patent pharmaceuticals. - Under the agreement, Adragos will allocate approximately 1.5 billion tablets per year of production capacity to Towa Pharmaceutical from its Kawagoe plant. - Adragos will expand annual solid-dosage capacity at the Kawagoe facility from 1.0 billion to 2.5 billion tablets through staged capital investment. - The partnership aims to strengthen Japan's domestic manufacturing resilience and long-term supply stability for off-patent medicines.
- Towa Pharmaceutical voluntarily recalled thousands of bottles of duloxetine 30 mg delayed-release capsules due to elevated levels of N-nitroso-duloxetine, a nitrosamine impurity. - The FDA has classified the recall as Class II, indicating the impurity may cause temporary or medically reversible adverse health consequences. - Nitrosamine impurities may increase cancer risk with long-term exposure above acceptable levels, though the FDA notes daily use at or below limits poses no elevated risk. - The affected lot is number 241180C with an expiration date of April 2027, distributed by Breckenridge Pharmaceutical Inc. in 1,000-capsule bottles.
- Nearly 375,000 bottles of duloxetine delayed-release capsules were voluntarily recalled by Towa Pharmaceutical and distributed by Breckenridge Pharmaceutical due to N-nitroso-duloxetine levels exceeding FDA limits. - The impurity belongs to the nitrosamine class, some of which are probable human carcinogens; long-term exposure above acceptable levels may increase cancer risk. - The FDA classified the recall as Class II, indicating a remote probability of serious adverse health consequences or temporary, medically reversible effects. - Patients are advised to contact their healthcare provider before stopping the medication, as abrupt discontinuation may pose greater risks than the impurity exposure.
- Japan's Ministry of Health, Labour and Welfare has approved Luye Pharma's innovative Rivastigmine Twice Weekly Transdermal Patch (Rivaluen® LA Patch) for mild to moderate Alzheimer's disease, marking the first extended-release rivastigmine transdermal formulation in the country. - The novel delivery system requires application only twice weekly versus traditional daily patches, potentially improving medication adherence in a patient population that often struggles with medication management as an early symptom of the disease. - Towa Pharmaceutical will commercialize the product in Japan under a 2020 licensing agreement, while the patch has already received approval in multiple European countries and China, with expansion planned for Southeast Asia and Latin America.
